Publications

Preclinical
Immuno-Oncology Summit
August 11, 2025
Engineering TrispecificT Cell Engager Leveraging Conditional CD28 Co-Stimulation to Treat Solid Tumors
Genevieve Desjardins, PhD
Preclinical
T cell Engager Summit
June 26, 2025
ZW209: A DLL3 Targeted Trispecific T Cell Engager with Conditional and Obligate cis CD28 Co-stimulation to Improve Responses in DLL3-Expressing Tumors
Nina Weisser, PhD
Clinical, ZW191
ESMO Gynaecological Cancers Congress
June 19, 2025
Design of a First-in-Human Multicentre Open-Label Study of ZW191, a Folate Receptor α–Targeting Antibody-Drug Conjugate Utilising a Novel TOPOIi Payload, in Participants With Advanced Solid Tumours: ZWI-ZW191-101
Sommerhalder et al.
Clinical, ZW171
ASCO
June 2, 2025
Design of a First-in-Human Multicenter Open-Label Study of ZW171, a Mesothelin x CD3–Targeting Bispecific T Cell Engager, in Participants With Advanced Solid Tumors: ZWI-ZW171-101
Johnson et al.
Preclinical, ZW1528
ATS
May 19, 2025
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Poffenberger et al.
Preclinical
Festival of Biologics
April 23, 2025
Trispecific T Cell Engagers Incorporating Conditional CD28 Co-Stimulation (TriTCE Co-Stim) to Improve Treatment Responses in Oncology
Chayne Piscitelli
Preclinical
AACR
April 30, 2025
ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
Preclinical
AACR
April 29, 2025
In vitro assays for prediction of ADC hematological toxicity: contribution of antibody, linker, and payload
Colombo et al.
Preclinical
AACR
April 28, 2025
High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection
Hogan et al.
Preclinical
AACR
April 28, 2025
Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7
Fung et al.
Preclinical
AACR
April 28, 2025
ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
Urosev et al.
ZW171
AACR
April 28, 2025
ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
Afacan et al.